相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER2 Gene Amplification in Breast Cancer A Rogues' Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations
Jane Starczynski et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Centromere 17 Copy Number Alteration Negative Prognostic Factor in Invasive Breast Cancer?
Stella Petroni et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Genetic heterogeneity in HER2 testing may influence therapy eligibility
Barbara Bernasconi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections
Hiroaki Nitta et al.
DIAGNOSTIC PATHOLOGY (2012)
Evaluation of Genetic Status of HER-2/neu and Aneusomy 17 by Fluorescence In Situ Hybridization and Comparison with Immunohistochemistry Assay from Indian Breast Cancer Patients
Prajakta Kokate et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2012)
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
Edith A. Perez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases
Martin C. Chang et al.
MODERN PATHOLOGY (2012)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Hyesil Seol et al.
MODERN PATHOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer
Anna Zaczek et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
Fast and Non-Toxic In Situ Hybridization without Blocking of Repetitive Sequences
Steen H. Matthiesen et al.
PLOS ONE (2012)
Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach
Tim J. A. Dekker et al.
BREAST CANCER RESEARCH (2012)
Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations Time for a New Look at How to Report Heterogeneity
Kimberly H. Allison et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a Clinically Relevant Definition
Alastair I. Bartlett et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Assessment of HER2 Gene Status in Breast Carcinomas With Polysomy of Chromosome 17
Semir Vranic et al.
CANCER (2011)
HER2 status in breast cancer: experience of a Spanish National Reference Centre
Marta Cuadros et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer
Xiaoli Zhu et al.
HUMAN PATHOLOGY (2011)
Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center
Sudha S. Murthy et al.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY (2011)
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer
M. Elizabeth Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Determining True HER2 Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy
Chun Hing Tse et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods
J. M. S. Bartlett et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
HER2 genetic heterogeneity in breast carcinoma
Christian Oehlschlegel et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
How Do You Tell Whether a Breast Cancer is HER2 Positive? Ongoing Studies Keep Debate in High Gear
Charlie Schmidt
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Implications of rarity of chromosome 17 polysomy in breast cancer
Cathy B. Moelans et al.
LANCET ONCOLOGY (2011)
Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer
Kristof Egervari et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
Her-2/neu Overexpression Due to Polysomy 17 in Breast Cancer: Molecular Testing to Guide Therapeutic Options
Rashmita Sahoo et al.
ONKOLOGIE (2011)
Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity
Shelly Gunn et al.
BMC CANCER (2010)
Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification
Cathy B. Moelans et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience
L. Zabaglo et al.
CANCER RESEARCH (2010)
Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer
Leona Downey et al.
CLINICAL CANCER RESEARCH (2010)
Management of small HER2-positive breast cancers
Susana Banerjee et al.
LANCET ONCOLOGY (2010)
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
Matteo Brunelli et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Guido Sauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer
Giuseppe Viale
JOURNAL OF PATHOLOGY (2009)
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis
Caterina Marchio et al.
JOURNAL OF PATHOLOGY (2009)
Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
Uma Krishnamurti et al.
MODERN PATHOLOGY (2009)
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
I-Tien Yeh et al.
MODERN PATHOLOGY (2009)
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
Monica M. Reinholz et al.
LANCET ONCOLOGY (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Determination of HER2 Amplification by In Situ Hybridization: When Should Chromosome 17 also be Determined?
John M. S. Bartlett et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
Laura Orlando et al.
BREAST (2008)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
Andrew D. Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
Isabelle Vanden Bempt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
C. L. Hyun et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
M. Hofmann et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast - A single institution experience
Raymond R. Tubbs et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2007)
HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17
Rosalba Torrisi et al.
EUROPEAN JOURNAL OF CANCER (2007)
Intratumoral heterogeneity of HER2/neu in breast cancer -: A rare event
Wedad Hanna et al.
BREAST JOURNAL (2007)
Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay?
Francoise Dignat-George et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus
Megan L. Troxell et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
Lissandra Dal Lago et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Gene amplification in cancer
Donna G. Albertson
TRENDS IN GENETICS (2006)
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+in immunohistochemical analysis
R. Merola et al.
EUROPEAN JOURNAL OF CANCER (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy
Christian Jackisch
ONCOLOGIST (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast - A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study
E Downs-Kelly et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining
JT Lewis et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice
Y Ma et al.
CLINICAL CANCER RESEARCH (2005)
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
M Salido et al.
BREAST CANCER RESEARCH (2005)
Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay
D Varshney et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
P Lal et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2003)
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
M Dowsett et al.
JOURNAL OF PATHOLOGY (2003)
Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma
AD Watters et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status
SJ Wang et al.
MODERN PATHOLOGY (2002)
Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization
F Tsukamoto et al.
CANCER CYTOPATHOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
